EATRIS ANNOUNCES NOVEL PUBLIC-PRIVATE COLLABORATION FOR IMAGING METHOD DEVELOPMENT IN INFLAMMATORY DISEASES
- Details
- Created on Thursday, 07 June 2018 13:19
International multi-site collaboration hub will implement new clinical imaging tools and deliver several projects per year with enhanced speed and throughput
Amsterdam, The Netherlands, June 4, 2018 - The European Infrastructure for Translational Medicine (EATRIS) has formed a collaboration with GlaxoSmithKline (GSK) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases.
iPEPS Biotech Startup Competition
- Details
- Created on Tuesday, 29 May 2018 13:59
The iPEPS innovation accelerator and Scientist.com are launching a call for biotech startups developing a novel therapeutic and/or diagnostic approach with a main focus on central nervous system (CNS) diseases (neuro-oncology, psychiatry, neurological disorders or preventive health).
Apply now until July 16th, and get awarded:
- Up to 6 months office/lab spaces at iPEPS
- Up to $10,000 in research services through Scientist.com marketplace (to be used within one year)
- Consulting with experts in preclinical/clinical development to build out your TPP (target product profile).
The winner of this competition and the runner-up will be announced at the end of September and will benefit of iPEPS mentoring to fast track the development of their projects in one of the most thriving research and innovation ecosystem in Paris.
Maladie d’Alzheimer : un rôle protecteur des dégénérescences neurofibrillaires ?
- Details
- Created on Wednesday, 23 May 2018 15:50
Plasma Amyloid is modulated by age and seasonal rhythms in mouse lemur primates
- Details
- Created on Wednesday, 23 May 2018 14:53
Accumulation of amyloid-β (Aβ) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. There is increasing interest in measuring levels of plasma Aβ since this could help in diagnosis of brain pathology. However, the value of plasma Aβ in such a diagnosis is still controversial and factors modulating its levels are still poorly understood.
